Novo Nordisk’s drug Saxenda is the current to strike a scarcity, as high need for weight-loss drugs triggers supply snags throughout the market.
Saxenda will have restricted accessibility through completion of the year, according to a notification published Tuesday on a US Food and Drug Administration database.
On a consumer-facing site for the drug, the business stated it is still making and delivering Saxenda however alerted of concerns filling prescriptions “for the remainder of 2023 and beyond.”
“We continue to see need for Saxenda boost at a considerable rate, leading to supply disturbances,“ a Novo representative stated in an e-mail.
Newer drugs from Novo Nordisk like Wegovy and Ozempic, along with Eli Lilly & Co.’s diabetes drug Mounjaro, have actually ended up being extremely popular in current months after research studies revealed they might assist clients lose lots of pounds. Only Wegovy is authorized by the FDA to deal with weight problems.
While Saxenda works likewise to these brand-new drugs, it’s less reliable and assists clients lose less weight. Recent lacks of Wegovy and Mounjaro, nevertheless, have actually resulted in restored interest. Prescriptions for Saxenda leapt almost 30,000 in between May 2023 and June 2023, according to Bloomberg Intelligence information, the most significant month-to-month dive over the previous 2 years.
On a Novo site for Wegovy, the business alerts potential clients versus changing to Saxenda, stating “we cannot guarantee supply to match the continuous rising demand for weight management medications.”